ERK1/2 activation is a therapeutic target in age-related macular degeneration.

MLA

Dridi, Sami, et al. “ERK1/2 Activation Is a Therapeutic Target in Age-Related Macular Degeneration.” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 34, Aug. 2012, pp. 13781–86. EBSCOhost, https://doi.org/10.1073/pnas.1206494109.

APA

Dridi, S., Hirano, Y., Tarallo, V., Kim, Y., Fowler, B. J., Ambati, B. K., Bogdanovich, S., Chiodo, V. A., Hauswirth, W. W., Kugel, J. F., Goodrich, J. A., Ponicsan, S. L., Hinton, D. R., Kleinman, M. E., Baffi, J. Z., Gelfand, B. D., & Ambati, J. (2012). ERK1/2 activation is a therapeutic target in age-related macular degeneration. Proceedings of the National Academy of Sciences of the United States of America, 109(34), 13781–13786. https://doi.org/10.1073/pnas.1206494109

Chicago

Dridi, Sami, Yoshio Hirano, Valeria Tarallo, Younghee Kim, Benjamin J Fowler, Balamurali K Ambati, Sasha Bogdanovich, et al. 2012. “ERK1/2 Activation Is a Therapeutic Target in Age-Related Macular Degeneration.” Proceedings of the National Academy of Sciences of the United States of America 109 (34): 13781–86. doi:10.1073/pnas.1206494109.